144 related articles for article (PubMed ID: 11379825)
1. Evaluating characteristics of patient selection and dropout rates.
Keith SJ
J Clin Psychiatry; 2001; 62 Suppl 9():11-4; discussion 15-6. PubMed ID: 11379825
[TBL] [Abstract][Full Text] [Related]
2. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
3. Dose selection and comparator drugs in schizophrenia research.
Kane JM
J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
[TBL] [Abstract][Full Text] [Related]
4. The statistical comparison of clinical trials.
Schooler NR
J Clin Psychiatry; 2001; 62 Suppl 9():35-7; discussion 38-9. PubMed ID: 11379830
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial design issues in schizophrenic research.
Casey DE
J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
[TBL] [Abstract][Full Text] [Related]
6. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
[TBL] [Abstract][Full Text] [Related]
7. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
9. Evaluating clinical trial data: outcome measures.
Conley RR
J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
[TBL] [Abstract][Full Text] [Related]
10. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
Goyal N; Gomeni R
Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
[TBL] [Abstract][Full Text] [Related]
11. Introduction: evaluating clinical trial data from schizophrenia research.
Tamminga CA
J Clin Psychiatry; 2001; 62 Suppl 9():3-4. PubMed ID: 11379829
[No Abstract] [Full Text] [Related]
12. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).
Boter H; Derks EM; Fleischhacker WW; Davidson M; Kahn RS;
J Clin Psychiatry; 2010 Jan; 71(1):58-65. PubMed ID: 19852905
[TBL] [Abstract][Full Text] [Related]
13. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
14. Interpretations and conclusions in the clinical trial.
Docherty JP
J Clin Psychiatry; 2001; 62 Suppl 9():40-3; discussion 44-5. PubMed ID: 11379831
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
[TBL] [Abstract][Full Text] [Related]
16. Relapse prevention and recovery in the treatment of schizophrenia.
Schooler NR
J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
[TBL] [Abstract][Full Text] [Related]
17. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
18. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
[TBL] [Abstract][Full Text] [Related]
19. The CATIE study and its implications for antipsychotic drug use.
Janicak PG
Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293
[No Abstract] [Full Text] [Related]
20. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
Sankaranarayanan J; Puumala SE
Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
